Adaptive Biotechnologies Corp(ADPT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADPT Adaptive Biotechnologies Corp

Closed Independence Day 07-02 16:00:00 EDT

21.19

-1.18

-5.27%

盘后21.00

-0.19-0.90%

19:06 EDT

High22.80	Low21.09	Vol3.39M
Open22.50	D1 Closing22.37	Amplitude7.64%
Mkt Cap3.39B	Tradable Cap2.49B	Total Shares159.76M
T/O73.39M	T/O Rate2.89%	Tradable Shares117.37M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ADPT","market":"US","secType":"STK","nameCN":"Adaptive Biotechnologies Corp","latestPrice":21.19,"timestamp":1783022400000,"preClose":22.37,"halted":0,"volume":3393925,"hourTrading":{"tag":"盘后","latestPrice":21,"preClose":21.19,"latestTime":"19:06 EDT","volume":218389,"amount":4627187.0098,"timestamp":1783033597965,"change":-0.19,"changeRate":-0.008966,"amplitude":0.011317},"delay":0,"changeRate":-0.052749217702279826,"floatShares":117369033,"shares":159760700,"eps":-0.325352,"marketStatus":"Closed Independence Day","change":-1.18,"latestTime":"07-02 16:00:00 EDT","open":22.495,"high":22.8,"low":21.09,"amount":73393957.335725,"amplitude":0.076442,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.325352,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1783324800000},"marketStatusCode":7,"adr":0,"listingDate":1561608000000,"exchange":"NASDAQ","adjPreClose":22.37,"preHourTrading":{"tag":"盘前","latestPrice":22.33,"preClose":22.37,"latestTime":"09:29 EDT","volume":3671,"amount":82429.90416600001,"timestamp":1782998999999,"change":-0.04,"changeRate":-0.001788,"amplitude":0.015561},"postHourTrading":{"tag":"盘后","latestPrice":21,"preClose":21.19,"latestTime":"19:06 EDT","volume":218389,"amount":4627187.0098,"timestamp":1783033597965,"change":-0.19,"changeRate":-0.008966,"amplitude":0.011317},"volumeRatio":0.8210981955980966,"impliedVol":0.8439,"impliedVolPercentile":0.5498},"requestUrl":"/m/hq/s/ADPT/wiki","defaultTab":"wiki","newsList":[{"id":"2648598420","title":"Adaptive Biotechnologies Chief Commercial Officer Imm Med Sharon Benzeno Sells 165,802 Shares for $3.73 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2648598420","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648598420?lang=en_us&edition=fundamental","pubTime":"2026-07-01 07:25","pubTimestamp":1782861942,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Chief Commercial Officer Imm Med Sharon Benzeno sells 165,802 shares for $3.73 millionAdaptive Biotechnologies officer Sharon Benzeno, chief commercial officer, immune medicin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL1g8wN4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies Chief Commercial Officer Imm Med Sharon Benzeno Sells 165,802 Shares for $3.73 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647588960","title":"Adaptive Biotechnologies Director Michelle Renee Griffin Disposes of 52,084 Common Shares Worth $1,051,855.12","url":"https://stock-news.laohu8.com/highlight/detail?id=2647588960","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647588960?lang=en_us&edition=fundamental","pubTime":"2026-06-30 07:50","pubTimestamp":1782777021,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies director Michelle Renee Griffin disposes of 52,084 common shares worth $1,051,855.12Adaptive Biotechnologies director Michelle Renee Griffin sold 52,084 common shares on June ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL7YxnJ4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies Director Michelle Renee Griffin Disposes of 52,084 Common Shares Worth $1,051,855.12","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647303075","title":"Adaptive Biotechnologies (ADPT) Plans A Business Split, Is The Valuation Already Full?","url":"https://stock-news.laohu8.com/highlight/detail?id=2647303075","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647303075?lang=en_us&edition=fundamental","pubTime":"2026-06-29 23:20","pubTimestamp":1782746449,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies (ADPT) is back in focus after announcing plans to separate its Minimal Residual Disease and Immune Medicine businesses, alongside completing a $300 million zero coupon convertible notes offering.\nSee our latest analysis for Adaptive Biotechnologies.\nThese separation plans and the recent convertible notes offering come on the back of strong momentum in Adaptive Biotechnologies' stock, with a 30 day share price return of 38.35% and a 1 year total shareholder return of...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/adaptive-biotechnologies-adpt-plans-a-business-split-is-the","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/adaptive-biotechnologies-adpt-plans-a-business-split-is-the","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647377105","title":"Adaptive Biotechnologies is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2647377105","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647377105?lang=en_us&edition=fundamental","pubTime":"2026-06-29 22:06","pubTimestamp":1782741960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADPT/analyst-ratings(END) Dow Jones NewswiresJune 29, 2026 10:06 ET","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647375409","title":"Adaptive Biotechnologies price target raised to $22 from $21 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2647375409","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647375409?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:00","pubTimestamp":1782730824,"startTime":"0","endTime":"0","summary":"Guggenheim raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $22 from $21 and keeps a Buy rating on the shares. The firm adjuste...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adaptive-biotechnologies-price-target-raised-to-22-from-21-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adaptive-biotechnologies-price-target-raised-to-22-from-21-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645008400","title":"Adaptive Biotechnologies Issues $345 Million Convertible Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2645008400","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645008400?lang=en_us&edition=fundamental","pubTime":"2026-06-23 05:38","pubTimestamp":1782164337,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies  said late Monday it has issued $345 million of 0% convertible senior notes due 2031, including the full exercise of an over-allotment option.Net proceeds were used among others for capped call transactions, share repurchase, and for the repayment of the OrbiMed purchase agreement, the company said in a filing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645774300","title":"Adaptive Biotechnologies Corp - Issues $345 Mln in 0% Convertible Senior Notes Due 2031 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2645774300","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645774300?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:08","pubTimestamp":1782158918,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nFWN42U0LK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645077439","title":"Adaptive Biotechnologies prices upsized USD 300 million 0% convertible senior notes offering due 2031","url":"https://stock-news.laohu8.com/highlight/detail?id=2645077439","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645077439?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:07","pubTimestamp":1782158878,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies priced an upsized private offering of USD 300 million 0% convertible senior notes due 2031, raised from USD 250 million.Settlement is scheduled for June 22, 2026; initial purchasers hold an option to buy up to an additional USD 45 million of notes.Net proceeds estimated at about USD 290.8 million, or about USD 334.5 million if the option is fully exercised.Proceeds earmarked to repay the OrbiMed Purchase Agreement, fund a capped call, repurchase USD 25 million of stock, support MRD initiatives.Initial conversion price set at about USD 24.11 per share; capped call cap price set at USD 34.44.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDLbwQ5DJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644720722","title":"Adaptive Biotechnologies CSO Harlan S. Robins sells 106,160 shares for $1.85 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2644720722","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644720722?lang=en_us&edition=fundamental","pubTime":"2026-06-18 08:11","pubTimestamp":1781741513,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Chief Scientific Officer Harlan S. Robins sold 106,160 common shares on June 15-16.Sales priced at $17.37, $18.01; holdings fell to 1,405,898 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDLbQYYnq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies CSO Harlan S. Robins sells 106,160 shares for $1.85 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644751747","title":"BUZZ-U.S. STOCKS ON THE MOVE-Jabil, BWX Technologies, Micron","url":"https://stock-news.laohu8.com/highlight/detail?id=2644751747","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644751747?lang=en_us&edition=fundamental","pubTime":"2026-06-17 23:42","pubTimestamp":1781710974,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Jabil, BWX Technologies, MicronWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nL6N42P12K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTHM","INLF","ECHO","SATS","ASTX","DSX","CME","VSTM","SOPH","AMAT","INTW","LZB","SNBRQ","ADPT","KLAC","BWXT","SNBR","SVAQ","TGE","HOOY","HOOX","CVNA","KMX","ASTN","JBL","HOOD","PTRN","HOOI","QURE","ASTS","WNC","CVNX","TXG","INTC","GNK","MU","SHAZ","LRCX","LINT","LDOS","EHGO","ADTX","WBX","SKIL","WDC","LRCU","KLAG","MUU","SATG","NEO","BIRD","ICCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644474097","title":"Adaptive Biotechnologies Price Target Maintained With a $22.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2644474097","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644474097?lang=en_us&edition=fundamental","pubTime":"2026-06-17 23:32","pubTimestamp":1781710320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADPT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 17, 2026 11:32 ET (15:32 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644745054","title":"Adaptive Biotechnologies prices $300M convertible senior note offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2644745054","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644745054?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:11","pubTimestamp":1781698290,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies (ADPT) “announced the pricing of its offering of $300 million aggregate principal amount of 0% convertible senior notes du...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adaptive-biotechnologies-prices-300m-convertible-senior-note-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adaptive-biotechnologies-prices-300m-convertible-senior-note-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644498743","title":"BUZZ-U.S. STOCKS ON THE MOVE-Intel, La-Z-Boy, AST SpaceMobile","url":"https://stock-news.laohu8.com/highlight/detail?id=2644498743","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644498743?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:35","pubTimestamp":1781696109,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Intel, La-Z-Boy, AST SpaceMobileWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslette","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nL6N42P0SY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4615","BK4585","LU0154236417.USD","LU0719512351.SGD","ADPT","BK4529","BK4588","LU0321505868.SGD","04335","BK4579","LU2357627491.SGD","BK4121","BK4575","LU2764263039.SGD","ASTX","BK4095","BK4550","BK4512","LU2148611432.USD","LU0321505439.SGD","BK4141","BK4515","BK4533","BK4543","BK4602","LINT","ASTN","BK4534","BK4527","LZB","BK4089","LU0149725797.USD","LU2089985449.USD","LU2764262908.HKD","LU2720916845.USD","BK4214","HK0000304805.HKD","IE000M9KFDE8.USD","BK4123","BK4554","LU2931357623.SGD","LU0097036916.USD","LU0006061336.USD","LU2764263203.CNY","ASTS","HK0000304797.USD","BK4516","LDOS","LU2543165471.USD","IE0009354923.USD","INTW","LU0082616367.USD","KMX","LU0081259029.USD","LU0274383776.USD","LU0859254822.USD","BK4535","INTC","BK4612","BK4605"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644438587","title":"BUZZ-Adaptive Biotechnologies up after boosted $300 mln convertible bond sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2644438587","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644438587?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:18","pubTimestamp":1781695107,"startTime":"0","endTime":"0","summary":"BUZZ-Adaptive Biotechnologies up after boosted $300 mln convertible bond sale** Shares of Adaptive Biotechnologies ADPT.O up 0.5% at $17.30 before the bell on Weds as co raises more capital than planned** Seattle, Washington-based ADPT announces pricing private offering of $300 mln 0% convertible bonds due 2031** Offering size increased from $250 mln; initial conversion price of $24.11 is 40% premium to stock's last sale of $17.22 on Tues** Co intends to use net offering proceeds to repay OrbiMed purchase agreement, for general purposes and opportunistic initiatives in Minimal Residual Disease  business** Late Mon, ADPT unveiled plans to separate its MRD and Immune Medicine businesses, with CEO and co-founder Chad Robins saying it's \"the best way to unlock the full potential of both businesses, increasing their impact on patients and creating long-term value for shareholders\"** ADPT stock closed down 1.4% on Tues for about $2.8 bln market cap. Stock up 6% YTD and 67% over the past 12 m","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nL6N42P0RI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BUZZ-Adaptive Biotechnologies up after boosted $300 mln convertible bond sale","news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644411717","title":"Adaptive Biotechnologies prices upsized USD 300 million 0% convertible senior notes offering due 2031","url":"https://stock-news.laohu8.com/highlight/detail?id=2644411717","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644411717?lang=en_us&edition=fundamental","pubTime":"2026-06-17 18:00","pubTimestamp":1781690450,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies priced an upsized USD 300 million private offering of 0% convertible senior notes due 2031, raised from USD 250 million.Deal includes a 13-day option for initial purchasers to buy up to an additional USD 45 million of notes.Net proceeds estimated at USD 290.8 million, rising to about USD 334.5 million if the option is fully exercised.Proceeds earmarked to repay the OrbiMed Purchase Agreement, fund a USD 22.3 million capped call, repurchase USD 25 million of stock.Notes convert at 41.48 shares per USD 1,000, implying a USD 24.11 conversion price; settlement scheduled for June 22, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL8JKdhl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4112","LU0314104364.USD","SG9999014013.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210149790.SGD","BK4588","BK4585","NDAQ","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","SG9999014021.USD","LU2095319765.USD","LU2210150020.SGD","SG9999014039.USD","IE00BN0W2V16.EUR","BK4121","IE00BGHQF748.EUR","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644174587","title":"Adaptive Biotechnologies - Prices $300 Mln 0% Convertible Senior Notes Due 2031","url":"https://stock-news.laohu8.com/highlight/detail?id=2644174587","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644174587?lang=en_us&edition=fundamental","pubTime":"2026-06-17 18:00","pubTimestamp":1781690400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nTUA8QYY0J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644717757","title":"Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2644717757","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644717757?lang=en_us&edition=fundamental","pubTime":"2026-06-17 18:00","pubTimestamp":1781690400,"startTime":"0","endTime":"0","summary":"Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibilityAdditional proceeds used to pay for the capped call with a premium of 100% and to repurchase $2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/17/3313253/0/en/Adaptive-Biotechnologies-Corporation-Prices-Upsized-300-Million-Convertible-Senior-Notes-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644715644","title":"MRD Spinoff And $250 Million Convertible Notes Could Be A Game Changer For Adaptive Biotechnologies (ADPT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644715644","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644715644?lang=en_us&edition=fundamental","pubTime":"2026-06-17 14:25","pubTimestamp":1781677527,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies recently completed a US$250,000,000 private offering of unsecured, senior, callable convertible notes due July 1, 2031, while also outlining plans to separate its profitable Minimal Residual Disease (MRD) unit from its Immune Medicine business.\nThe combination of business separation and new convertible debt signals a meaningful reshaping of Adaptive’s capital structure and business focus, with MRD positioned as the primary engine and Immune Medicine seeking growth...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/mrd-spinoff-and-250-million-convertible-notes-could-be-a-gam","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/mrd-spinoff-and-250-million-convertible-notes-could-be-a-gam","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7095","MRD.AU","ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644766759","title":"Analysts Are Bullish on Top Healthcare Stocks: Pasithea Therapeutics Corp (KTTA), Adaptive Biotechnologies (ADPT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644766759","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644766759?lang=en_us&edition=fundamental","pubTime":"2026-06-16 23:50","pubTimestamp":1781625010,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pasithea Therapeutics Corp (KTTA) and Adaptive Biote...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-pasithea-therapeutics-corp-ktta-adaptive-biotechnologies-adpt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-pasithea-therapeutics-corp-ktta-adaptive-biotechnologies-adpt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KTTA","BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643875264","title":"Adaptive Biotechnologies offers to sell $250M in 2031 convertible senior notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2643875264","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643875264?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:18","pubTimestamp":1781612288,"startTime":"0","endTime":"0","summary":"Last night, the company stated: “Adaptive Biotechnologies (ADPT) announced its intention to offer, subject to market and other conditions, $250 mil...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adaptive-biotechnologies-offers-to-sell-250m-in-2031-convertible-senior-notes-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adaptive-biotechnologies-offers-to-sell-250m-in-2031-convertible-senior-notes-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.adaptivebiotech.com","stockEarnings":[{"period":"1week","weight":0.0464},{"period":"1month","weight":0.3996},{"period":"3month","weight":0.4308},{"period":"6month","weight":0.3319},{"period":"1year","weight":0.8458},{"period":"ytd","weight":0.3048}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":-0.0195},{"period":"3month","weight":0.1356},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2004},{"period":"ytd","weight":0.0922}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.006662},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.034164},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.108302},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.084119},{"month":5,"riseRate":0.571429,"avgChangeRate":0.103614},{"month":6,"riseRate":0.857143,"avgChangeRate":0.145465},{"month":7,"riseRate":0.375,"avgChangeRate":-0.002427},{"month":8,"riseRate":0.571429,"avgChangeRate":0.074393},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.065733},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.030408},{"month":11,"riseRate":0.714286,"avgChangeRate":0.049327},{"month":12,"riseRate":0.714286,"avgChangeRate":0.032336}],"exchange":"NASDAQ","name":"Adaptive Biotechnologies Corp","nameEN":"Adaptive Biotechnologies Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Adaptive Biotechnologies Corp(ADPT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Adaptive Biotechnologies Corp(ADPT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Adaptive Biotechnologies Corp,ADPT,Adaptive Biotechnologies Corp股票,Adaptive Biotechnologies Corp股票老虎,Adaptive Biotechnologies Corp股票老虎国际,Adaptive Biotechnologies Corp行情,Adaptive Biotechnologies Corp股票行情,Adaptive Biotechnologies Corp股价,Adaptive Biotechnologies Corp股市,Adaptive Biotechnologies Corp股票价格,Adaptive Biotechnologies Corp股票交易,Adaptive Biotechnologies Corp股票购买,Adaptive Biotechnologies Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Adaptive Biotechnologies Corp(ADPT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Adaptive Biotechnologies Corp(ADPT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}